

Drug resistance interpretation: PR

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:

L10I99%
seen:4,533

•

G16E99%
seen:4,663

•

M36I99%
seen:7,282

•

N37K99%
seen:7,403

•

R41K99%
seen:7,515

•

R57RK99%
seen:7,524

•

Q61E99%
seen:5,347

•

I62IM99%
seen:5,293

•

L63T99%
seen:5,264

•

H69K99%
seen:5,140

•

L89M99%
seen:4,636

•

I93L99%
seen:4,241

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

M184V99%
seen:4,238

NNRTI Mutations:

P225PH99%
seen:4,525

RT Other Mutations:

P4PS99%
seen:4,580

•

V35T99%
seen:4,147

•

E36EV99%
seen:4,147

•

T39E99%
seen:4,579

•

K122KE99%
seen:4,62

•

I135L99%
seen:4,538

•

I142IV99%
seen:4,235

•

K173AT99%
seen:2,952

•

Q174K99%
seen:2,952

•

D177E99%
seen:2,95

•

I178IM99%
seen:2,952

•

T200A99%
seen:3,952

•

Q207E99%
seen:4,11

•

R211Q99%
seen:3,957

•

V245Q99%
seen:3,952

•

A272P99%
seen:3,95

•

K275NQ99%
seen:3,94

•

K277KR99%
seen:4,114

•

T286A99%
seen:3,952

•

E291D99%
seen:3,95

•

V292I99%
seen:3,95

•

I293V99%
seen:3,95

•

V311TA99%
seen:4,211

•

I329IV99%
seen:4,138

•

A354S99%
seen:3,124

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Low-Level Resistance

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Potential Low-Level Resistance

emtricitabine (FTC)

High-Level Resistance

lamivudine (3TC)

High-Level Resistance

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Low-Level Resistance

efavirenz (EFV)

Intermediate Resistance

etravirine (ETR)

Susceptible

nevirapine (NVP)

Intermediate Resistance

rilpivirine (RPV)

Susceptible

RT comments

NRTI

- M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

- P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
M184V	15	-10	-10	10	60	60	-10

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
P225PH	20	45	0	45	0

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:

S17N99%
seen:54,336

•

D25E99%
seen:17,787

•

V31I99%
seen:17,787

•

G59E99%
seen:11,545

•

I84M99%
seen:5,835

•

L101I99%
seen:387

•

T112V99%
seen:711

•

T124N99%
seen:2,335

•

D167E99%
seen:11,817

•

K173R99%
seen:11,817

•

V201I99%
seen:8,745

•

L234I99%
seen:4,527

•

S255G99%
seen:4,145

Integrase Strand Transfer Inhibitors

bictegravir (BIC)

Susceptible

cabotegravir (CAB)

Susceptible

dolutegravir (DTG)

Susceptible

elvitegravir (EVG)

Susceptible

raltegravir (RAL)

Susceptible

Mutation scoring: IN	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for INSTI.